Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients

Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378, Sep 2020
Recovery at day 7 10% primary improvement lower risk ← → higher risk Ivermectin  Chachar et al.  LATE TREATMENT RCT Is late treatment with ivermectin beneficial for COVID-19? RCT 50 patients in India Improved recovery with ivermectin (not stat. sig., p=0.5) c19early.org Chachar et al., Int. J. Sciences-35, Sep 2020 0 0.5 1 1.5 2+ RR
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Download Meta Analysis
Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recovery at day 7.
This is the 5th of 53 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.000000087.
This is the 9th of 106 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001.
Important missing comments or errors? Let us know.
risk of no recovery at day 7, 10.0% lower, RR 0.90, p = 0.50, treatment 9 of 25 (36.0%), control 10 of 25 (40.0%), NNT 25, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chachar et al., 30 Sep 2020, Randomized Controlled Trial, India, peer-reviewed, 6 authors, dosage 36mg, 12mg stat, 12mg after 12 hours, 12mg after 24 hours.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 India United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Chad Syria India favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 India United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Benin Serbia CAR Syria India favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Aijaz Zeeshan Khan Chachar, Khurshid Ahmad Khan, Mohsin Asif, Khushbakht Tanveer, Arous Khaqan, Rabia Basri
International Journal of Sciences, doi:10.18483/ijsci.2378
Background:The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Objectives: To assess the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria. Study Settings: Fatima Memorial Hospital, Lahore Study Design: Open label randomized control trial. Duration of Study: From 1 st May, 2020 to 30 th June, 2020.Patients & Methods: Sample size and technique: Sample size was 50 patients; 25 patients were kept in control group and 25 patients were kept in experimental group. Results: There were total 50 patients, divided into two groups case and control group.The mean age of the participants was 40.60 ± 17 and out of those 31 (62%) were male and 19 (38%) were females. Cough was observed more in case group (p= 0.049). Fever, myalgias and dyspnea were the commonest symptoms in both the groups (p= 1.000). Diarrhea and vomiting were more common in control group (p=0.0001, p= 0.042 respectively). On follow up at day 7, patients were stratified as asymptomatic and symptomatic. Amongst the case group, out of 25 patients, 16(64%) patients were asymptomatic and rest of the 9(36%) patients was asymptomatic. In control group, out of 25 patients, 15(60%) patients were asymptomatic and rest of the 10(40%) patients was asymptomatic. p-value (0.500). Statistically there was no significant difference between case group who were given ivermectin along with symptomatic treatment and control group who were only given symptomatic treatment without ivermectin, being asymptomatic on day 7 at follow up. p-value (0.500
References
Bai, Yao, Wei, Tian, Jin et al., Presumed asymptomatic carrier transmission of COVID-19, Jama, doi:10.1001/jama.2020.2565
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral research, doi:10.1016/j.antiviral.2020.104787
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients, doi:10.21203/rs.3.rs-38896/v1
David, What is the role of antiparasitic drug ivermectin in the treatment of corona virus disease, doi:10.26434/chemrxiv.11875446.v1
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, The Journal of Antibiotics, doi:10.1038/s41429-020-0336-z
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle, Journal of medical virology, doi:10.1002/jmv.25678
Patel, Usefulness of Ivermectin in COVID-19 Illness, doi:10.1101/2020.06.06.20124461
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19, medRxiv, doi:10.26434/chemrxiv.11875446.v1
Sohrabi, Alsafi, Neill, Khan, Kerwan et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), International Journal of Surgery, doi:10.1016/j.ijsu.2020.03.036
Yavuz, Ünal, Antiviral treatment of COVID-19, Turkish Journal of Medical Sciences, doi:10.3906/sag-2004-145
DOI record: { "DOI": "10.18483/ijsci.2378", "ISSN": [ "2305-3925", "2410-4477" ], "URL": "http://dx.doi.org/10.18483/ijSci.2378", "alternative-id": [ "92020092378" ], "author": [ { "affiliation": [], "family": "Zeeshan Khan Chachar", "given": "Aijaz", "sequence": "first" }, { "affiliation": [], "family": "Ahmad Khan", "given": "Khurshid", "sequence": "additional" }, { "affiliation": [], "family": "Asif", "given": "Mohsin", "sequence": "additional" }, { "affiliation": [], "family": "Tanveer", "given": "Khushbakht", "sequence": "additional" }, { "affiliation": [], "family": "Khaqan", "given": "Arous", "sequence": "additional" }, { "affiliation": [], "family": "Basri", "given": "Rabia", "sequence": "additional" } ], "container-title": "International Journal of Sciences", "container-title-short": "ijSciences", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 10, 9 ] ], "date-time": "2020-10-09T03:28:22Z", "timestamp": 1602214102000 }, "deposited": { "date-parts": [ [ 2020, 10, 9 ] ], "date-time": "2020-10-09T03:28:23Z", "timestamp": 1602214103000 }, "indexed": { "date-parts": [ [ 2024, 3, 8 ] ], "date-time": "2024-03-08T12:31:16Z", "timestamp": 1709901076463 }, "is-referenced-by-count": 19, "issue": "09", "issued": { "date-parts": [ [ 2020 ] ] }, "journal-issue": { "issue": "09", "published-online": { "date-parts": [ [ 2020 ] ] } }, "language": "en", "member": "7748", "original-title": [], "page": "31-35", "prefix": "10.18483", "published": { "date-parts": [ [ 2020 ] ] }, "published-online": { "date-parts": [ [ 2020 ] ] }, "publisher": "Alkhaer Publications", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://www.ijsciences.com/pub/article/2378" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Materials Science" ], "subtitle": [], "title": "Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients", "type": "journal-article", "volume": "9" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0